Publications
Addressing the systemic challenges of underinvestment in prevention
8 June 2026
Prevention of ill-health is an underexploited tool for protecting health systems…
The impact of inflation on incremental costs in HTA
4 June 2026
Inflation reshapes the economic landscape in which new treatments are evaluated.…
The value of fast diagnostics in time-critical infections
20 April 2026
Advancing earlier intervention in time‑critical infections Sepsis continues to…
Evaluating novel antimicrobials within EU joint clinical assessments
16 April 2026
Antimicrobial resistance (AMR) is a growing global health and economic threat.…
Insights
Germany’s drug-pricing dilemma: Why Europe’s pivotal market holds the key to the MFN debate
25 June 2026
Much of the Most-Favoured-Nation debate asks whether the United States can…
The cost of inaction on LDL cholesterol
24 June 2026
This Insight is based on the WHA79 panel discussion "Lowering Cholesterol,…
One Europe, one assessment? Unpacking the European Joint Clinical Assessment
28 May 2026
As the first EU Joint Clinical Assessment reports approach, national HTA systems…
Two numbers, one decision: making climate-health valuation usable across sectors
18 May 2026
An OHE insight, ahead of OHE’s participation in the Health Diplomacy House…
Robust analysis, real-world problems
OHE research supports pragmatic solutions and stronger policy decisions
Areas of expertise
OHE’s expertise covers a wide range of topics
Health Technology Assessment (HTA)
The impact of inflation on incremental costs in HTA
Inflation reshapes the economic landscape in which new treatments are evaluated. Yet cost-effectiveness thresholds tend to…
One Europe, one assessment? Unpacking the European Joint Clinical Assessment
As the first EU Joint Clinical Assessment reports approach, national HTA systems across Europe are already adapting to a…
Drug Development/R&D
Is the revised Congressional Budget Office model of new drug development fit for purpose?
As U.S. drug-pricing policy changes accelerate, policymakers need reliable ways to understand how reduced pharmaceutical…
Evaluating novel antimicrobials within EU joint clinical assessments
Antimicrobial resistance (AMR) is a growing global health and economic threat. It is responsible for an additional 9.5…
Digital Health
The true cost and burden of frontotemporal dementia: Early insights into a pressing challenge
In recognition of Frontotemporal Dementia Awareness Week, OHE shares ongoing work quantifying the disease burden and…
OHE’s submission for the DHSC’s next 10 years of planning
This Insight summarises the recommendations OHE submitted towards the Department of Health & Social Care’s consultation…
Prevention
The cost of inaction on LDL cholesterol
This Insight is based on the WHA79 panel discussion "Lowering Cholesterol, Increasing Impact: The Case for Earlier Action…
Addressing the systemic challenges of underinvestment in prevention
Prevention of ill-health is an underexploited tool for protecting health systems and societies. It offers the potential to…